Zojwalla Naseem Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
4
Insider Sells Sum
$459,752.01

Insider Activity of Zojwalla Naseem

According to the SEC Form 4 filings, Zojwalla Naseem, being in a position of

  1. Chief Medical Officer at Olema Pharmaceuticals, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 269509 shares for $7.53M,
    over all time since 2023-11-21, has bought 0 shares, and sold 311870 shares for $7.99M.

Biography of Zojwalla Naseem

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $000
Sells
 $7,530,1483100

Comparison of Insiders on Amount of Buys and Sells

2025-12-23SaleOlema Pharmaceuticals, Inc.
OLMA
Chief Medical Officer
99,509
0.1423%
$27.66$2.75M-53.98%
2025-12-22SaleOlema Pharmaceuticals, Inc.
OLMA
Chief Medical Officer
100,000
0.1449%
$28.04$2.8M-54.72%
2025-12-19SaleOlema Pharmaceuticals, Inc.
OLMA
Chief Medical Officer
70,000
0.1029%
$28.20$1.97M-54.3%
2024-12-11SaleOlema Pharmaceuticals, Inc.
OLMA
CHIEF MEDICAL OFFICER
14,522
0.0264%
$8.68$125,994-37.22%
2024-12-10SaleOlema Pharmaceuticals, Inc.
OLMA
CHIEF MEDICAL OFFICER
13,283
0.0233%
$9.37$124,462-45.23%
2023-11-22SaleOlema Pharmaceuticals, Inc.
OLMA
CHIEF MEDICAL OFFICER
7,095
0.0131%
$13.89$98,550-13.42%
2023-11-21SaleOlema Pharmaceuticals, Inc.
OLMA
CHIEF MEDICAL OFFICER
7,461
0.0142%
$14.84$110,747-16.06%
Total: 7
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.